Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BIO
stocks logo

BIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
709.32M
+6.27%
2.857
-1.49%
603.43M
+3.08%
2.454
-3.4%
672.41M
+3.19%
2.869
+9.93%
Estimates Revision
The market is revising Downward the revenue expectations for Bio-Rad Laboratories, Inc. (BIO) for FY2025, with the revenue forecasts being adjusted by -0.16% over the past three months. During the same period, the stock price has changed by 8.34%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+5.08%
In Past 3 Month
Stock Price
Go Up
up Image
+8.34%
In Past 3 Month
Wall Street analysts forecast BIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO is 369.25 USD with a low forecast of 325.00 USD and a high forecast of 437.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast BIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO is 369.25 USD with a low forecast of 325.00 USD and a high forecast of 437.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 320.060
sliders
Low
325.00
Averages
369.25
High
437.00
Current: 320.060
sliders
Low
325.00
Averages
369.25
High
437.00
Citi
Buy
maintain
$350 -> $375
2025-10-30
Reason
Citi
Price Target
$350 -> $375
2025-10-30
maintain
Buy
Reason
Citi raised the firm's price target on Bio-Rad to $375 from $350 and keeps a Buy rating on the shares. The firm cites higher peer multiples for the target bump post the company's Q3 report.
Wells Fargo
Equal Weight
maintain
$265 -> $340
2025-10-30
Reason
Wells Fargo
Price Target
$265 -> $340
2025-10-30
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Bio-Rad to $340 from $265 and keeps an Equal Weight rating on the shares. The firm says shares of Bio-Rad should be flat on the in-line quarter and stable full year guide. Not surprisingly, Bio-Rad is cautious on 2026 growth prospects, but still expects to deliver margin expansion even on muted revenue growth, Wells adds.
Wells Fargo
Brandon Couillard
Equal Weight
maintain
$245 -> $265
2025-08-01
Reason
Wells Fargo
Brandon Couillard
Price Target
$245 -> $265
2025-08-01
maintain
Equal Weight
Reason
Wells Fargo analyst Brandon Couillard raised the firm's price target on Bio-Rad to $265 from $245 and keeps an Equal Weight rating on the shares. The firm believes shares of Bio-Rad should open higher on the solid Q2 beat and upward guidance revision. Commentary on U.S. academic demand was surprisingly constructive. Overall, a positive step toward "new-ish" management building more credibility with Street, says Wells.
UBS
NULL -> Buy
maintain
$310 -> $325
2025-08-01
Reason
UBS
Price Target
$310 -> $325
2025-08-01
maintain
NULL -> Buy
Reason
UBS raised the firm's price target on Bio-Rad to $325 from $310 and keeps a Buy rating on the shares.
Wells Fargo
Equal Weight
downgrade
$260 -> $245
2025-06-08
Reason
Wells Fargo
Price Target
$260 -> $245
2025-06-08
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Bio-Rad to $245 from $260 and keeps an Equal Weight rating on the shares. The firm reduced estimates to reflect revised assumptions for life science growth in the second half of 2025 and 2026.
Wells Fargo
Brandon Couillard
Hold
Maintains
$320 → $270
2025-04-17
Reason
Wells Fargo
Brandon Couillard
Price Target
$320 → $270
2025-04-17
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bio Rad Laboratories Inc (BIO.N) is 30.42, compared to its 5-year average forward P/E of 36.20. For a more detailed relative valuation and DCF analysis to assess Bio Rad Laboratories Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
36.20
Current PE
30.42
Overvalued PE
47.63
Undervalued PE
24.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
22.39
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
29.53
Undervalued EV/EBITDA
15.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.69
Current PS
0.00
Overvalued PS
6.37
Undervalued PS
3.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 333305.8% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BIO News & Events

Events Timeline

(ET)
2025-08-01
10:00:09
Bio-Rad rises 15.8%
select
2025-07-31 (ET)
2025-07-31
16:28:26
Bio-Rad sees FY25 non-GAAP, currency-neutral revenue growth of flat to up 1%
select
2025-07-31
16:27:21
Bio-Rad reports Q2 adjusted EPS $2.61, consensus $1.75
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-25TipRanks
3 Stocks Signaling 'Buy' Opportunities for Investors Based on Technical Analysis

  • Market Volatility and Technical Analysis: Amid market fluctuations, investors can leverage technical analysis to identify promising stock opportunities, with TipRanks highlighting Wintrust Financial, Bio-Rad Laboratories, and Agree Realty as Strong Buy candidates.

  • Wintrust Financial Overview: Wintrust Financial is experiencing an upward trend, supported by a Strong Buy rating and 12 bullish signals indicating strong momentum according to TipRanks’ technical analysis.

  • Bio-Rad Laboratories Insights: Bio-Rad Laboratories also holds a Strong Buy consensus, with a positive Rate of Change (ROC) of 1.69, suggesting upward momentum and a Buy signal for the stock.

  • Agree Realty Corporation Analysis: Agree Realty is rated a Strong Buy based on moving average consensus, with a positive ROC of 2.75, indicating strong upward momentum and a favorable Buy signal.

[object Object]
Preview
9.5
10-30Yahoo Finance
Bio-Rad Laboratories Reports Increase in Q3 Non-GAAP Earnings and Revenue
  • Earnings Report: Bio-Rad Laboratories (BIO) announced Q3 non-GAAP earnings of $2.26 per diluted share.
  • Access Requirement: Users need to sign in to access their portfolio information.
[object Object]
Preview
4.0
10-23NASDAQ.COM
BIO Surpasses Average Analyst Expectations

  • Current Stock Performance: Bio-Rad Laboratories Inc's shares have surpassed the average analyst 12-month target price of $331.40, trading at $333.97/share, prompting potential analyst reactions regarding valuation adjustments.

  • Analyst Target Range: Within the Zacks coverage universe, analyst targets for Bio-Rad vary significantly, with one analyst setting a low target of $265.00 and another as high as $437.00, indicating a standard deviation of $68.171.

  • Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock is on a trajectory towards higher targets or if it has become overvalued, suggesting a potential need to reassess their positions.

  • Analyst Ratings Overview: The article references a rating scale from 1 (Strong Buy) to 5 (Strong Sell) for Bio-Rad, reflecting the collective insights of analysts covering the company.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bio Rad Laboratories Inc (BIO) stock price today?

The current price of BIO is 320.06 USD — it has decreased -0.09 % in the last trading day.

arrow icon

What is Bio Rad Laboratories Inc (BIO)'s business?

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

arrow icon

What is the price predicton of BIO Stock?

Wall Street analysts forecast BIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO is 369.25 USD with a low forecast of 325.00 USD and a high forecast of 437.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bio Rad Laboratories Inc (BIO)'s revenue for the last quarter?

Bio Rad Laboratories Inc revenue for the last quarter amounts to 653.00M USD, increased 0.50 % YoY.

arrow icon

What is Bio Rad Laboratories Inc (BIO)'s earnings per share (EPS) for the last quarter?

Bio Rad Laboratories Inc. EPS for the last quarter amounts to -12.70 USD, decreased -154.41 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bio Rad Laboratories Inc (BIO)'s fundamentals?

The market is revising Downward the revenue expectations for Bio-Rad Laboratories, Inc. (BIO) for FY2025, with the revenue forecasts being adjusted by -0.16% over the past three months. During the same period, the stock price has changed by 8.34%.
arrow icon

How many employees does Bio Rad Laboratories Inc (BIO). have?

Bio Rad Laboratories Inc (BIO) has 7700 emplpoyees as of December 05 2025.

arrow icon

What is Bio Rad Laboratories Inc (BIO) market cap?

Today BIO has the market capitalization of 8.63B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free